On November 05, 2015 Geron Corporation (Nasdaq:GERN) reported that three abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition to be held in Orlando, Florida from December 5-8, 2015 (Press release, Geron, NOV 5, 2015, View Source;p=RssLanding&cat=news&id=2107371 [SID:1234507994]). The abstracts were published today on the ASH (Free ASH Whitepaper) website at www.hematology.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentations

Two abstracts containing clinical data on imetelstat were selected for oral presentation. One abstract contains an analysis of preliminary safety and efficacy data from a pilot study of patients with a subtype of myelodysplastic syndromes known as refractory anemia with ring sideroblasts. The second abstract contains an analysis of mutations detected in essential thrombocythemia patients treated with imetelstat. The abstract supplements a prior analysis of JAK2V617F and CALR mutations presented at the ASH (Free ASH Whitepaper) Annual Meeting in December 2014.

Title: Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis (Abstract #55)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Early and Late Stage Trials in MPN
Session Date: Saturday, December 5, 2015
Session Time: 9:30 a.m. ET – 11:00 a.m. ET
Presentation Time: 9:30 a.m. ET

Title: Dynamics of Mutations in Patients with ET Treated with Imetelstat (Abstract #57)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Early and Late Stage Trials in MPN
Session Date: Saturday, December 5, 2015
Session Time: 9:30 a.m. ET – 11:00 a.m. ET
Presentation Time: 10:00 a.m. ET

Poster Presentation

One abstract containing non-clinical data on imetelstat was selected for presentation as a poster. In this study, the investigators evaluated the activity of imetelstat in a non-clinical model of acute myeloid leukemia, to potentially support broader clinical development of the drug.

Title: Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced by DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status (Abstract #1267)
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
Session Date: Saturday, December 5, 2015
Session Time: 5:30 p.m. – 7:30 p.m. ET

In accordance with ASH (Free ASH Whitepaper) policies, abstracts submitted to the ASH (Free ASH Whitepaper) Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the ASH (Free ASH Whitepaper) Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the ASH (Free ASH Whitepaper) Annual Meeting.